Does rosuvastatin delay progression of atherosclerosis in people with HIV infection at moderate cardiovascular risk? A randomized, placebo-controlled trial
Latest Information Update: 26 Aug 2021
At a glance
- Drugs Rosuvastatin (Primary) ; Cobicistat; Ritonavir
- Indications Atherosclerosis
- Focus Therapeutic Use
- 16 Aug 2021 Results of substudy analysing impact of 48 weeks of rosuvastatin therapy on inflammation and immune activation in PWH at moderate cardiovascular disease risk, published in the Journal of Infectious Diseases
- 26 Nov 2020 Primary endpoint (Progression of Carotid Intima Media Thickness) has not been met as per the results published in the AIDS.
- 26 Nov 2020 Results published in the AIDS